Stock COPN COSMO PHARMACEUTICALS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Market Closed - Swiss Exchange
Other stock markets
 11:31:35 2024-06-07 am EDT 		5-day change 1st Jan Change
74.8 CHF +3.46% Intraday chart for Cosmo Pharmaceuticals N.V. +5.65% +46.95%
Apr. 26 Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 CI
Apr. 25 Cosmo Pharmaceuticals Names New CEO, Chairman MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Written Proxy
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Proposed Amendments to the Renumeration Policy
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Notification of number of shares as of 6 June 2024
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Explanatory Notes
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Convening Notice
PU
Cosmo Pharmaceuticals N : Written proxy – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Proposed Amendments to the Remuneration Policy – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Notification of number of shares 6 June 2024 – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Explanatory notes – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Convening notice – EGM 5 July 2024
PU
Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down
MT
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX
NE
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
NE
Cosmo Pharmaceuticals N : reports excellent final Full Year 2023 financial results – Increases operating profit guidance for 2024 – Dividend of € 2.00 per share will be proposed at EGM on 5 July 2024
PU
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting
NE
Cosmo Pharmaceuticals N : ’ Shareholders approve all Agenda Items at Annual General Meeting
PU
Cosmo Pharmaceuticals N : Niall Donnelly CV
PU
Cosmo Pharmaceuticals N : Convening notice
PU
Cosmo Pharmaceuticals N : Written Proxy
PU
Cosmo Pharmaceuticals N : Explanatory notes
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COPN Stock
  4. News Cosmo Pharmaceuticals N.V.